SG Americas Securities
EDIT icon

SG Americas Securities’s Editas Medicine EDIT Stock Holding History

SG Americas Securities’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,136
Closed -$32K – 3429
2026
Q1 		$32K Sell
13,136
-3,666
-22% -$7.76K ﹤0.01% 3061
2025
Q4 		$34K Buy
16,802
+2,048
+14% +$5.91K ﹤0.01% 3407
2025
Q3 		$51K Buy
+14,754
New +$41.2K ﹤0.01% 3201
2025
Q2 		– Sell
-31,516
Closed -$37K – 3117
2025
Q1 		$37K Sell
31,516
-50,153
-61% -$73.8K ﹤0.01% 3301
2024
Q4 		$104K Buy
81,669
+41,573
+104% +$106K ﹤0.01% 2713
2024
Q3 		$137K Buy
+40,096
New +$175K ﹤0.01% 2806
2024
Q1 		– Sell
-32,859
Closed -$333K – 3088
2023
Q4 		$333K Sell
32,859
-17,887
-35% -$157K ﹤0.01% 1745
2023
Q3 		$396K Buy
+50,746
New +$435K ﹤0.01% 1918
2023
Q2 		– Sell
-10,522
Closed -$76K – 2512
2023
Q1 		$76K Buy
+10,522
New +$93.5K ﹤0.01% 2989
2022
Q4 		– Sell
-24,459
Closed -$299K – 3135
2022
Q3 		$299K Sell
24,459
-26,447
-52% -$412K ﹤0.01% 1997
2022
Q2 		$602K Buy
50,906
+12,992
+34% +$174K 0.01% 1796
2022
Q1 		$721K Buy
+37,914
New +$705K 0.01% 1645
2021
Q4 		– Sell
-14,070
Closed -$578K – 3494
2021
Q3 		$578K Buy
14,070
+11,539
+456% +$632K ﹤0.01% 2366
2021
Q2 		$143K Sell
2,531
-10,322
-80% -$381K ﹤0.01% 2492
2021
Q1 		$540K Buy
12,853
+4,095
+47% +$233K ﹤0.01% 1976
2020
Q4 		$614K Sell
8,758
-21,441
-71% -$881K ﹤0.01% 1833
2020
Q3 		$847K Buy
30,199
+4,292
+17% +$140K 0.01% 1283
2020
Q2 		$766K Buy
25,907
+14,658
+130% +$383K 0.01% 1677
2020
Q1 		$223K Buy
11,249
+7,265
+182% +$183K ﹤0.01% 2429
2019
Q4 		$118K Buy
+3,984
New +$99.5K ﹤0.01% 2852
2018
Q3 		– Sell
-3,087
Closed -$111K – 3222
2018
Q2 		$111K Sell
3,087
-6,919
-69% -$245K ﹤0.01% 3002
2018
Q1 		$332K Buy
+10,006
New +$357K ﹤0.01% 2120
2017
Q1 		– Sell
-19,641
Closed -$319K – 3332
2016
Q4 		$319K Buy
+19,641
New +$298K ﹤0.01% 1991
2016
Q3 		– Sell
-14,597
Closed -$356K – 3362
2016
Q2 		$356K Sell
14,597
-18,887
-56% -$637K ﹤0.01% 1866
2016
Q1 		$1.16M Buy
+33,484
New +$880K 0.01% 1217

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SG Americas Securities's EDIT Position: Q2 2026 in Review

SG Americas Securities sold out of Editas Medicine (EDIT) in Q2 2026, closing a stake of 13,136 shares — an estimated $32K sold.

SG Americas Securities first reported a position in EDIT in Q1 2016 and held it in 25 quarters. The position peaked at $1.16M in Q1 2016. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • SG Americas Securities reported no remaining Editas Medicine position as of Q2 2026 after selling out during the quarter.
  • SG Americas Securities sold 13,136 Editas Medicine shares in Q2 2026, an estimated $32K.
  • SG Americas Securities first reported a position in Editas Medicine in Q1 2016 and held it in 25 quarters.
  • SG Americas Securities's Editas Medicine position peaked at $1.16M in Q1 2016.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.